Potential of IL-10 as Targeted Therapy in Severe COVID-19 Patients

Nur Fadhilah, - and Gatot Soegiarto, - and Theresia Indah Budhy S., - (2021) Potential of IL-10 as Targeted Therapy in Severe COVID-19 Patients. Malaysian Journal of Medicine and Health Sciences, 17 (Sup2). pp. 165-168. ISSN 16758544

[img] Text (Artikel)
1. Full Text_Artikel 22.pdf

Download (1MB)
[img] Text (Similarity)
2. Turnitin_Artikel 22.pdf

Download (1MB)
[img] Text (Peer Review)
Karil Artikel 22.pdf

Download (653kB)
Official URL: https://medic.upm.edu.my/upload/dokumen/2021043007...

Abstract

A brand new virus that is known as Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the cause of this new disease called Coronavirus Disease 2019 (COVID-19). This new disease may lead to severe illnesses and eventually become fatal due to many complications related to cytokine storms. Cytokine storm could be described as pro-inflammatory cytokine response that is not controlled due to infection and other stimuli. The increase in cytokine levels can cause multiple organ systems damages. To protect the patient from tissue damage caused by the pro-inflammatory cytokine, a balanced immune response is needed. Many efforts have been tested to manipulate or prevent the cytokine storm. One of the potential targets is IL-10. IL-10 is a key role cytokine. The information regarding IL-10 that is currently available will be reviewed in this article, its role in the cytokine storm, and its potential as a curative agent in COVID-19.

Item Type: Article
Uncontrolled Keywords: COVID-19, Cytokine storms, IL-10, Therapeutic target
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine
Divisions: 01. Fakultas Kedokteran > Ilmu Penyakit Dalam
Creators:
CreatorsNIM
Nur Fadhilah, -UNSPECIFIED
Gatot Soegiarto, -NIDN8888210016
Theresia Indah Budhy S., -NIDN0007066104
Depositing User: arys fk
Date Deposited: 23 Oct 2022 23:17
Last Modified: 23 Oct 2022 23:17
URI: http://repository.unair.ac.id/id/eprint/118335
Sosial Share:

Actions (login required)

View Item View Item